Tissue Regenix Group Regulatory News (TRX)

Tissue Regenix Group plc

DermaPure receives Medicare coverage & reimbursement

YORK, 5 March 2015 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, today announces its DermaPure® dermal allograft has received notice of Local Coverage Determination (LCD) from the Medicare Administrative Contractor (Novitas) that oversees Jurisdiction J-H and Jurisdiction J-L, effective April 9, 2015. This represents a key milestone in the post-acute or outpatient care setting for the usage and reimbursement of DermaPure® for patient wound care. After receiving a Q-code in January from the Center for Medicare and Medicaid Services ("CMS"), the US Federal Government funded health programme, LCD approval from the various jurisdictions is the final step needed that enables the outpatient medical facility to obtain reimbursement for the product for qualified patients.

The J-H jurisdiction spans the states of Colorado, New Mexico, Oklahoma, Texas, Louisiana, Mississippi and Arkansas and the J-L jurisdiction spans Washington DC, Delaware, Maryland, New Jersey and Pennsylvania with total health care coverage for the two jurisdictions of 8.9 million Medicare beneficiaries. This decision will allow greater access to DermaPure® for clinicians and provide an advanced treatment option for patients suffering from chronic and acute wounds meeting medical necessity criteria.

Antony Odell, CEO of Tissue Regenix commented:

"DermaPure® has achieved outstanding clinical results in numerous acute care institutions following its introduction in June of last year. We are delighted with the opportunity to expand our reach to help patients in the post-acute environment, including wound care centers and ambulatory surgical centers. These facilities represent a significant usage of skin substitutes for wound care treatment."

Tissue Regenix will continue actively engaging with the other LCD jurisdiction contractors to further the benefits of DermaPure to healthcare providers and patients in other US geographies.

ENDS

For Further Information

Tissue Regenix Group Plc: +44 19 0443 5176

Antony Odell

Ian Jefferson

Jefferies International Ltd: +44 20 7029 8000

Simon Hardy

Harry Nicholas

Tulchan Communications: +44 207 353 4200

Tom Buchanan

Victoria Huxster

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.